Johannes Petutschnigg

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial

John G.F. Cleland, João Pedro Ferreira, Beatrice Mariottoni et al. · European Heart Journal · 2020 · 143 citations · Full text

Medicine, Cardiology, Pharmacology +16

Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

João Pedro Ferreira, Job A.J. Verdonschot, Ping Wang et al. · JACC Heart Failure · 2021 · 90 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +11

Effects of Spironolactone on Serum Markers of Fibrosis in People at High Risk of Developing Heart Failure: Rationale, Design and Baseline Characteristics of a Proof-of-Concept, Randomised, Precision-Medicine, Prevention Trial. The Heart OMics in AGing (HOMAGE) Trial

Pierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni et al. · European Journal of Heart Failure · 2020 · 68 citations

Medicine, Cardiology, Pharmacology +16

The Diagnostic and Prognostic Value of Galectin-3 in Patients at Risk for Heart Failure with Preserved Ejection Fraction: Results from the DIAST-CHF Study

Tobias Daniel Trippel, Meinhard Mende, Hans‐Dirk Düngen et al. · ESC Heart Failure · 2021 · 47 citations · Full text

Medicine, Cardiology, Internal Medicine +14

Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial

Susana Ravassa, Begoña López, João Pedro Ferreira et al. · European Journal of Heart Failure · 2021 · 28 citations · Full text

Medicine, Cardiology, Pharmacology +17